Influenza is an acute respiratory infectious disease caused by influenza viruses, and it poses a serious threat to global public health. High-risk groups include the elderly, infants and young children, pregnant women, and patients with chronic underlying diseases. 

These groups are prone to developing severe illness after infection, which can lead to serious complications and even death. Early antiviral treatment is key to reducing the rate of severe illness and death. 

Currently, authoritative guidelines at home and abroad recommend early, single-agent antiviral therapy as the standard regimen. However, anti-influenza virus monotherapy has problems such as drug resistance and poor therapeutic effect. 

To address these problems, this consensus was developed by organizing experts from the departments of Infectious Diseases, Respiratory Medicine, Critical Care Medicine, and Pharmacy. These experts systematically sorted out domestic and international evidence on combined antiviral therapy for influenza and formulated expert recommendations on combined antiviral therapy for influenza in specific populations.

流感是由流感病毒引起的急性呼吸道传染病，对全球公共卫生构成严重威胁。老年人群、婴幼儿、孕产妇以及患有慢性基础性疾病的患者等高危人群感染后易发展为重症，可能出现严重并发症甚至死亡。

这些群体在感染后易发展为重症，可导致严重并发症甚至死亡。早期抗病毒治疗是降低重症率和死亡率的关键。

目前，国内外权威指南均推荐将早期单药抗病毒治疗作为标准方案。然而，抗流感病毒单药治疗存在耐药性和疗效不佳等问题。

为解决这些问题，本共识组织感染病学、呼吸病学、重症医学及药学等多领域专家，系统梳理了国内外关于流感联合抗病毒治疗的循证证据，并针对特定人群制定了流感联合抗病毒治疗的专家建议。